ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the receipt of a $5 million payment from SynBioTx as part of an ongoing license and collaboration agreement, totaling $15 million received to date with the expectation of an additional $35 million. The agreement supports the development of IMM2510 and IMM27M, novel therapies targeting cancer growth and immune response enhancement. Investors are advised to exercise caution as the company progresses towards the potential market release of these therapies.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.
